Supportive Care in Cancer

, Volume 20, Issue 8, pp 1771–1777 | Cite as

Perspectives toward oral mucositis prevention from parents and health care professionals in pediatric cancer

  • Marie-Chantal Ethier
  • Dean A. Regier
  • Deborah Tomlinson
  • Peter Judd
  • John Doyle
  • Adam Gassas
  • Ahmed Naqvi
  • Lillian Sung
Original Article

Abstract

Purpose

The objectives of this study were: (1) to describe parents and health care professionals (HCPs) perceived importance of oral mucositis prevention in children with cancer; (2) To describe utilities and willingness-to-pay (WTP) to prevent mucositis.

Methods

Respondents included parents of children receiving intensive chemotherapy for leukemia/lymphoma or undergoing stem cell transplantation and HCPs caring for children with cancer. Importance of mild and severe oral mucositis was estimated using a visual analogue scale (VAS). Mucositis-associated utilities were elicited using the time trade-off technique (TTO). WTP to avoid mucositis was obtained using contingent valuation. These techniques quantify how much time or money the participant is willing to relinquish in order to prevent mucositis.

Results

Eighty-two parents and 60 HCPs were included. Parents and HCPs believed mild mucositis to be of similar importance (median VAS 2.5 versus 3.6; P = 0.357) while parents considered severe mucositis less important than HCPs (median VAS 8.3 versus 9.0; P < 0.0001). No differences in parent versus HCP responses were seen with TTO (mild or severe mucositis) and most parents were not willing to trade any survival time to prevent severe mucositis. Parents were willing to pay significantly more than HCPs to prevent mild mucositis (average median WTP $1,371 CAN vs. $684 CAN, P = 0.031). No differences were seen in WTP to prevent severe mucositis.

Conclusions

Parents and HCP believe severe mucositis to be important, although it is more important to HCPs. Parents would not be willing to reduce life expectancy to eliminate mucositis.

Keywords

Mucositis Pediatric Time trade-off Visual analogue scale Willingness-to-pay Preferences 

References

  1. 1.
    Bellm LA, Cunningham G, Durnell L et al (2002) Defining clinically meaningful outcomes in the evaluation of new treatments for oral mucositis: oral mucositis patient provider advisory board. Cancer Investig 20:793–800CrossRefGoogle Scholar
  2. 2.
    Bennett K, Torrance G, Tugwell P (1991) Methodologic challenges in the development of utility measures of health-related quality of life in rheumatoid arthritis. Control Clin Trials 12:118S–128SPubMedCrossRefGoogle Scholar
  3. 3.
    Bobinac A, Van Exel NJ, Rutten FF, Brouwer WB (2010) Willingness to pay for a quality-adjusted life-year: the individual perspective. Value Health 13:1046–1055PubMedCrossRefGoogle Scholar
  4. 4.
    Carroll AE, Downs SM (2009) Improving decision analyses: parent preferences (utility values) for pediatric health outcomes. J Pediatr 155:21–25, 25 e21–25PubMedCrossRefGoogle Scholar
  5. 5.
    Cheng KK, Goggins WB, Lee VW, Thompson DR (2008) Risk factors for oral mucositis in children undergoing chemotherapy: a matched case–control study. Oral Oncol 44:1019–1025PubMedCrossRefGoogle Scholar
  6. 6.
    Diez L (1998) Assessing the willingness of parents to pay for reducing postoperative emesis in children. Pharmacoeconomics 13:589–595PubMedCrossRefGoogle Scholar
  7. 7.
    Donaldson C (2001) Eliciting patients’ values by use of ‘willingness to pay’: letting the theory drive the method. Heal Expect 4:180–188CrossRefGoogle Scholar
  8. 8.
    Donaldson C, Birch S, Gafni A (2002) The distribution problem in economic evaluation: income and the valuation of costs and consequences of health care programmes. Heal Econ 11:55–70CrossRefGoogle Scholar
  9. 9.
    Druley TE, Hayashi R, Mansur DB et al (2009) Early outcomes after allogeneic hematopoietic SCT in pediatric patients with hematologic malignancies following single fraction TBI. Bone Marrow Transplant 43:307–314PubMedCrossRefGoogle Scholar
  10. 10.
    Drummond M, Sculpher M, Torrance G, O’Brien B, Stoddart G (2005) Methods for the economic evaluation of health care programmes. Oxfor University Press, OxfordGoogle Scholar
  11. 11.
    Elting LS, Cooksley CD, Chambers MS, Garden AS (2007) Risk, outcomes, and costs of radiation-induced oral mucositis among patients with head-and-neck malignancies. Int J Radiat Oncol Biol Phys 68:1110–1120PubMedCrossRefGoogle Scholar
  12. 12.
    Figliolia SL, Oliveira DT, Pereira MC et al (2008) Oral mucositis in acute lymphoblastic leukaemia: analysis of 169 paediatric patients. Oral Dis 14:761–766PubMedCrossRefGoogle Scholar
  13. 13.
    Froberg DG, Kane RL (1989) Methodology for measuring health-state preferences-I: measurement strategies. J Clin Epidemiol 42:345–354PubMedCrossRefGoogle Scholar
  14. 14.
    Hanemann W (1984) Welfare evaluations in contingent valuation experiments with discrete responses. Am J Agric Econ 66:159–332CrossRefGoogle Scholar
  15. 15.
    Karthaus M, Rosenthal C, Ganser A (1999) Prophylaxis and treatment of chemo- and radiotherapy-induced oral mucositis—are there new strategies? Bone Marrow Transplant 24:1095–1108PubMedCrossRefGoogle Scholar
  16. 16.
    Lee SJ, Neumann PJ, Churchill WH, Cannon ME, Weinstein MC, Johannesson M (1997) Patients’ willingness to pay for autologous blood donation. Health Policy 40:1–12PubMedCrossRefGoogle Scholar
  17. 17.
    Lee SK, Penner PL, Cox M (1991) Comparison of the attitudes of health care professionals and parents toward active treatment of very low birth weight infants. Pediatrics 88:110–114PubMedGoogle Scholar
  18. 18.
    Lieu TA, Ray GT, Ortega-Sanchez IR, Kleinman K, Rusinak D, Prosser LA (2009) Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster. Pharmacoeconomics 27:1005–1016PubMedCrossRefGoogle Scholar
  19. 19.
    Locatelli F, Testi AM, Bernardo ME et al (2009) Clofarabine, cyclophosphamide and etoposide as single-course re-induction therapy for children with refractory/multiple relapsed acute lymphoblastic leukaemia. Br J Haematol 147:371–378PubMedCrossRefGoogle Scholar
  20. 20.
    Meyerhoff AS, Weniger BG, Jacobs RJ (2001) Economic value to parents of reducing the pain and emotional distress of childhood vaccine injections. Pediatr Infect Dis J 20:S57–S62PubMedCrossRefGoogle Scholar
  21. 21.
    Naraine VS, Risebrough NA, Oh P et al (2002) Health-related quality-of-life treatments for severe haemophilia: utility measurements using the Standard Gamble technique. Haemophilia 8:112–120PubMedCrossRefGoogle Scholar
  22. 22.
    Neumann PJ, Johannesson M (1994) The willingness to pay for in vitro fertilization: a pilot study using contingent valuation. Med Care 32:686–699PubMedCrossRefGoogle Scholar
  23. 23.
    Nonzee NJ, Dandade NA, Patel U et al (2008) Evaluating the supportive care costs of severe radiochemotherapy-induced mucositis and pharyngitis: results from a Northwestern University Costs of Cancer Program pilot study with head and neck and nonsmall cell lung cancer patients who received care at a county hospital, a Veterans Administration hospital, or a comprehensive cancer care center. Cancer 113:1446–1452PubMedCrossRefGoogle Scholar
  24. 24.
    Rhodes ET, Prosser LA, Lieu TA, Songer TJ, Ludwig DS, Laffel LM (2011) Preferences for type 2 diabetes health states among adolescents with or at risk of type 2 diabetes mellitus. Pediatr Diabetes (in press)Google Scholar
  25. 25.
    Ryan M, Watson V (2009) Comparing welfare estimates from payment card contingent valuation and discrete choice experiments. Heal Econ 18:389–401CrossRefGoogle Scholar
  26. 26.
    Saigal S, Stoskopf BL, Feeny D et al (1999) Differences in preferences for neonatal outcomes among health care professionals, parents, and adolescents. JAMA 281:1991–1997PubMedCrossRefGoogle Scholar
  27. 27.
    Sonis ST (2007) Pathobiology of oral mucositis: novel insights and opportunities. J Support Oncol 5:3–11PubMedGoogle Scholar
  28. 28.
    Sonis ST, Oster G, Fuchs H et al (2001) Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin Oncol 19:2201–2205PubMedGoogle Scholar
  29. 29.
    Spielberger R, Stiff P, Bensinger W et al (2004) Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590–2598PubMedCrossRefGoogle Scholar
  30. 30.
    Von Neumann J, Morgenstern O (1953) Theory of games and economic behavior. Wiley, New YorkGoogle Scholar
  31. 31.
    Wasserfallen JB, Currat-Zweifel C, Cheseaux JJ, Hofer M, Fanconi S (2006) Parents’ willingness to pay for diminishing children’s pain during blood sampling. Paediatr Anaesth 16:11–18PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Marie-Chantal Ethier
    • 1
  • Dean A. Regier
    • 5
  • Deborah Tomlinson
    • 1
  • Peter Judd
    • 2
    • 4
  • John Doyle
    • 3
  • Adam Gassas
    • 3
  • Ahmed Naqvi
    • 3
  • Lillian Sung
    • 1
    • 3
    • 6
  1. 1.Program in Child Health Evaluative SciencesThe Hospital for Sick ChildrenTorontoCanada
  2. 2.Department of DentistryThe Hospital for Sick ChildrenTorontoCanada
  3. 3.Division of Haematology/OncologyThe Hospital for Sick ChildrenTorontoCanada
  4. 4.Department of Dentistry and PaediatricsUniversity of TorontoTorontoCanada
  5. 5.Fred Hutchinson Cancer Research CenterSeattleUSA
  6. 6.27 King’s College CircleTorontoCanada

Personalised recommendations